| Not Yet Recruiting | A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease NCT07078955 | BRIM Biotechnology Inc. | Phase 2 |
| Completed | Tolerability and Efficacy Study of Reinnerva/Lubristil+G vs Vismed NCT07422259 | Medivis SRL | N/A |
| Completed | Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya NCT05918406 | Oyster Point Pharma, Inc. | Phase 4 |
| Unknown | Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients Wi NCT05618730 | Eximore Ltd. | Phase 1 |
| Completed | Levocarnitine for Dry Eye in Sjogren's Syndrome NCT03953703 | Vanderbilt University Medical Center | Phase 2 |
| Unknown | Treatment of Dry Eye Disease Using Pro-ocular™ - A Proof of Concept, Safety, and Efficacy Study NCT04884217 | PharmaDax Inc. | Phase 2 |
| Completed | Differential Diagnosis of Sjögren's Versus Non-Sjögren's Dry Eye NCT04493658 | Johns Hopkins University | — |
| Completed | Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fittin NCT04649177 | Boston Sight | N/A |
| Completed | A Randomized Study of Smile Exercise for Dry Eye NCT04421300 | Zhongshan Ophthalmic Center, Sun Yat-sen University | N/A |
| Completed | Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry E NCT04147650 | Aurinia Pharmaceuticals Inc. | Phase 2 / Phase 3 |
| Completed | Tavilermide Ophthalmic Solution for the Treatment of Dry Eye NCT03925727 | Mimetogen Pharmaceuticals USA, Inc. | Phase 3 |
| Withdrawn | Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease NCT03408015 | University of Alabama at Birmingham | Phase 4 |
| Completed | Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops NCT03706443 | Ohio State University | N/A |
| Withdrawn | Repository Corticotropin Injection in Keratoconjunctivitis Sicca NCT03398018 | University of Alabama at Birmingham | Phase 4 |
| Unknown | Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye NCT03436576 | Pontificia Universidad Catolica de Chile | Phase 3 |
| Completed | Tear Production by Nasal Neurostimulation Compared to Active Control NCT02970799 | Oculeve, Inc. | N/A |
| Completed | An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca NCT02845674 | Sun Pharmaceutical Industries Limited | Phase 3 |
| Completed | Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease NCT02819284 | Kala Pharmaceuticals, Inc. | Phase 3 |
| Completed | Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease NCT02813265 | Kala Pharmaceuticals, Inc. | Phase 3 |
| Completed | Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator NCT02798289 | Oculeve, Inc. | N/A |
| Completed | Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca NCT02688556 | Sun Pharmaceutical Industries Limited | Phase 3 |
| Completed | A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participant NCT02680158 | Oculeve, Inc. | N/A |
| Completed | A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease NCT02665234 | Mimetogen Pharmaceuticals USA, Inc. | Phase 3 |
| Completed | A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye NCT02634853 | Mimetogen Pharmaceuticals USA, Inc. | Phase 3 |
| Completed | Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator NCT02526290 | Oculeve, Inc. | N/A |
| Completed | Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Si NCT02254265 | Sun Pharmaceutical Industries Limited | Phase 2 / Phase 3 |
| Completed | Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease NCT02188160 | Kala Pharmaceuticals, Inc. | Phase 2 |
| Completed | A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye NCT02117687 | Allergan | Phase 4 |
| Completed | A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye NCT02139033 | Ocusoft, Inc. | Phase 4 |
| Completed | Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome NCT02066896 | Federal University of São Paulo | N/A |
| Completed | A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Ey NCT02121301 | Mitotech, SA | Phase 2 |
| Completed | To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca NCT01900249 | Rigel Pharmaceuticals | Phase 2 |
| Completed | Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye NCT01817582 | Bausch & Lomb Incorporated | Phase 2 |
| Completed | Ocular Manifestations in Rheumatic Diseases NCT03753893 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | — |
| Completed | Effects of Dry Eye Treatments on the Ocular Surface NCT01797822 | Baylor College of Medicine | Phase 4 |
| Completed | A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease NCT01733992 | Rigel Pharmaceuticals | Phase 1 |
| Completed | Effect of Controlled Adverse Environment (CAE) on Tear Film Stability NCT01547936 | ORA, Inc. | — |
| Completed | Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OP NCT01421498 | Shire | Phase 3 |
| Completed | Trial of CF101 to Treat Patients With Dry Eye Disease NCT01235234 | Can-Fite BioPharma | Phase 3 |
| Withdrawn | A Study Of Tasocitinib In Dry Eye Subjects NCT01226680 | Pfizer | Phase 2 |
| Terminated | Omega-3 Fatty Acid Supplements and Dry Eye NCT01213342 | Ohio State University | N/A |
| Completed | Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central NCT01057147 | Kubota Vision Inc. | Phase 2 |
| Completed | Dry Eye Assessment and Management: Feasibility Study NCT01102257 | Asbell, Penny, M.D. | Phase 2 / Phase 3 |
| Completed | Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye NCT01027013 | Kubota Vision Inc. | Phase 2 |
| Completed | Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye NCT00987727 | Allergan | Phase 4 |
| Completed | TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease NCT00848198 | TearLab Corporation | — |
| Completed | A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Voluntee NCT00851734 | Lux Biosciences, Inc. | Phase 1 |
| Completed | Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome NCT00788229 | Dhp Korea Co., Ltd. | Phase 2 |
| Completed | Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye NCT00883649 | Virginia Eye Consultants | N/A |
| Completed | Tear Film Break-up Time After Instillation of Artificial Tears NCT00681265 | Calm Water Therapeutics LLC | N/A |
| Completed | Goblet Cell Response and Dry Eye Symptoms After PRK and LASIK NCT00411827 | Walter Reed National Military Medical Center | N/A |
| Completed | Acupuncture Treatment of Dry Eye NCT00554879 | Walter Reed Army Medical Center | N/A |
| Completed | Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca NCT00349466 | Can-Fite BioPharma | Phase 2 |
| Completed | Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome NCT00426543 | University of Copenhagen | Phase 2 |
| Completed | Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Res NCT00407043 | Ophthalmic Consultants of Long Island | Phase 4 |
| Completed | Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points NCT00345241 | University of Texas Southwestern Medical Center | N/A |
| Completed | Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctiv NCT00128245 | Novartis | Phase 2 |
| Completed | Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease NCT00717418 | Allergan | — |
| Completed | Study of Rebamipide Eye Drops to Treat Dry Eye NCT00201955 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
| Completed | Study of Rebamipide Eye Drops to Treat Dry Eye NCT00201981 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
| Completed | Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye NCT00037661 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome NCT00025818 | Allergan | Phase 3 |
| Completed | Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops NCT00001731 | National Eye Institute (NEI) | Phase 2 |